Eye injection for wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years or older.
- You must have a type of wet age-related macular degeneration (AMD) with new, leaking blood vessels under the retina, and you must not have had any prior treatment for it.
- You must be willing to use reliable birth control during the study and for 3 months after the last dose, if you or your partner could become pregnant.
- You cannot have had a stroke or heart attack within the last 6 months, or have uncontrolled high blood pressure (above 180/100).
- You cannot have severe eye conditions unrelated to AMD, or a history of eye surgery for retinal or other problems (except uncomplicated cataract removal).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests a new eye injection (GenSci148) for people with wet age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. The injection may help reduce swelling and abnormal blood vessel growth in the retina, which can improve or stabilise vision.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This study tests an investigational drug given as an eye injection to treat wet age-related macular degeneration (AMD) in people who have not been treated before. The goal is to see if it can help improve vision and reduce the need for frequent injections.
This trial tests a new eye drop called NT-101 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if the drops can improve vision and reduce fluid in the eye, possibly as a less invasive alternative to injections.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.